Imidazole → 2-(Tert-butyldimethylsilyloxy)-5-(2,3-difluorophenyl)cycloheptanol
反応式
[F:1][C:2]1[C:7]([F:8])=[CH:6][CH:5]=[CH:4][C:3]=1[CH:9]1[CH2:15][CH2:14][CH:13]([OH:16])[CH:12]([OH:17])[CH2:11][CH2:10]1.[Si:18](Cl)([C:21]([CH3:24])([CH3:23])[CH3:22])([CH3:20])[CH3:19].N1C=CN=C1.CCCCCC.CCOC(C)=O>CN(C=O)C.O>[Si:18]([O:17][CH:12]1[CH2:11][CH2:10][CH:9]([C:3]2[CH:4]=[CH:5][CH:6]=[C:7]([F:8])[C:2]=2[F:1])[CH2:15][CH2:14][CH:13]1[OH:16])([C:21]([CH3:24])([CH3:23])[CH3:22])([CH3:20])[CH3:19]参加物
実験手順
In a 250 mL round-bottomed flask (t=g) was added 5-(2,3-difluorophenyl)cycloheptane-1,2-diol (1.454 g, 6.0 mmol) (crude material, azeotroped with dry benzene) in DMF (20 mL) to give a colorless solution. TBS-Cl (0.995 g, 6.60 mmol) and imidazole (0.980 g, 14.40 mmol) were added, and the mixture was stirred at room temperature for 5 hours. TLC (2/1 hexane/EtOAc) indicated complete conversion to two main spots. It was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried with Na2SO4 and concentrated to a colorless oil. Purification by FCC up to 30% EtOAc/hexane afforded the desired mono-protected product as a broad peak. The product fractions were pooled and concentrated to a colorless oil (1.79 g, 84% for two steps). 1H NMR (400 MHz, CDCl3) δ 7.02-6.85 (m, 3H), 3.98-3.70 (m, 2H), 3.18-3.02 (m, 1H), 2.15-1.82 (m, 4H), 1.80-1.45 (m, 4H), 0.91 (s, 9H), 0.90 (2s, 6H).
後処理
- customto give a colorless solution
- extractionextracted with EtOAc twice
- washThe combined organic layers were washed with brine
- dry with materialdried with Na2SO4
- concentrationconcentrated to a colorless oil
- customPurification by FCC up to 30% EtOAc/hexane
- customafforded the desired mono-protected product as a broad peak
- concentrationconcentrated to a colorless oil (1.79 g, 84% for two steps)
出典と根拠
- ORDレコード
- ord-87818234208642a9b11068433e3f2ec5
- 出典データセット
- uspto-grants-2011_10
- 特許番号
- US08044043B2
反応ノート
読み込み中…